Number of Inquiries for a Second Course of Teprotumumab in the US Over Four Years
Author(s)
Alexandra Eddy, MSc1, Louisa Pericleous, PhD1, Selva Jeganathan, PhD2, Margarita R. Ochoa-maya, MD3, Galin Spicer, MD2.
1Amgen, Thousand Oaks, CA, USA, 2AMGEN, Thousand Oaks, CA, USA, 3AMGEN, Cohasset, MA, USA.
1Amgen, Thousand Oaks, CA, USA, 2AMGEN, Thousand Oaks, CA, USA, 3AMGEN, Cohasset, MA, USA.
OBJECTIVES: Thyroid Eye Disease (TED) is a debilitating autoimmune condition with limited treatment options. In 2020, teprotumumab-trbw (TEPEZZA®) became the first FDA-approved treatment specifically for TED. This retrospective cohort study assessed number of inquiries for a second course of teprotumumab in the U.S over four years.
METHODS: Deidentified data from 29,093 US patients with TED, from January 2020 (US Marketing approval) to September 2024, were obtained from an Amgen internal TED database. Data is collected through HCPs, patients and infusion centers and includes requests for treatment with teprotumumab, infusion counts, treatment discontinuation, and second-course requests. Treatment requests are submitted via the Patient Enrollment Form (PEF) by physicians or office staff but must first progress through various insurance approval steps before treatment with teprotumumab is administered. The proportion of physician inquiries for a second course was calculated among patients who completed all 8 consecutive infusions at first course without a COVID related supply disruption between December 2020 and April 2021.
RESULTS: Of the 14,294 patients who completed all 8 consecutive teprotumumab infusions at first course, a second course was requested for 1,546 patients (10.8%). The mean age was 59 years (SD=13), mean weight was 78 kg (SD=21), and 75% were female. The mean time from completion of first course to requesting a second course was 13.5 months (SD=8) and 96.6% (1,493/1,546) completed their first course within a mean duration of 5.1 months.
CONCLUSIONS: This data is derived from the largest teprotumumab cohort available to date. This study examines only the proportion of patients for whom a second course of treatment was requested. Results indicated that although some patients with TED required further treatment, the number of inquiries for a second course of teprotumumab was limited to 10.8% among patients completing 8 infusions at first course without disruption over 4 years.
METHODS: Deidentified data from 29,093 US patients with TED, from January 2020 (US Marketing approval) to September 2024, were obtained from an Amgen internal TED database. Data is collected through HCPs, patients and infusion centers and includes requests for treatment with teprotumumab, infusion counts, treatment discontinuation, and second-course requests. Treatment requests are submitted via the Patient Enrollment Form (PEF) by physicians or office staff but must first progress through various insurance approval steps before treatment with teprotumumab is administered. The proportion of physician inquiries for a second course was calculated among patients who completed all 8 consecutive infusions at first course without a COVID related supply disruption between December 2020 and April 2021.
RESULTS: Of the 14,294 patients who completed all 8 consecutive teprotumumab infusions at first course, a second course was requested for 1,546 patients (10.8%). The mean age was 59 years (SD=13), mean weight was 78 kg (SD=21), and 75% were female. The mean time from completion of first course to requesting a second course was 13.5 months (SD=8) and 96.6% (1,493/1,546) completed their first course within a mean duration of 5.1 months.
CONCLUSIONS: This data is derived from the largest teprotumumab cohort available to date. This study examines only the proportion of patients for whom a second course of treatment was requested. Results indicated that although some patients with TED required further treatment, the number of inquiries for a second course of teprotumumab was limited to 10.8% among patients completing 8 infusions at first course without disruption over 4 years.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
HSD77
Topic
Health Service Delivery & Process of Care
Disease
Rare & Orphan Diseases, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)